Infertility
Conditions
Interventions
Experimental group:Anxinbao (Recombinant Human Follitropin for Injection)
Sponsors
Guangdong Maternal and Child Health Hospital
Eligibility
Sex/Gender
Female
Age
20 Years to 38 Years
Inclusion criteria
Inclusion criteria: 1. Aged 20 to 38 years; 2. Receiving IVF/ICSI treatment for the first time; 3. Normal ovarian reserve: regular menstrual cycle (25-35 days), AMH > 1.1 ng/mL, FSH 6; 4. Participate in the study voluntarily and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Known allergy to main ingredients or excipients of Anxinbao (recombinant human follicle-stimulating hormone for injection); 2. Malignant tumors of hypothalamus, pituitary, ovary, uterus or breast; 3. Primary ovarian failure; 4. Abnormal uterine bleeding; 5. Severe intrauterine adhesions, severe adenomyosis and other diseases affecting embryo implantation; 6. Acute infection of urinary and reproductive system; 7. History of recurrent abortion; 8. BMI>=30 kg/m^2; 9. There are systemic diseases, endocrine diseases or metabolic abnormalities of clinical significance; 10. Other conditions deemed unsuitable for participation in this clinical study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ongoing pregnancy rate after the first embryo transfer; | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of oocytes retrieved;Rate of transferable embryos;Embryo implantation rate;Clinical pregnancy rate;Live birth rate; | — |
Countries
China
Contacts
Public ContactLiu Fenghua
Guangdong Maternal and Child Health Hospital
Outcome results
None listed